The Latest Breaking News from Johnson & Johnson (

A U.S. appeals court has dismissed the bankruptcy case filed by a Johnson & Johnson spinoff company. Around 40,000 cancer patients have filed suit, alleging the powder was contaminated with asbestos.

The 4-decades long effort to create an AIDS vaccine suffered a blow with news that a vaccine in a late stage trial was discontinued because results showed it to be ineffective. What are the obstacles?

Big Pharma stalwarts are on the brink of launching the first-ever RSV vaccines, potentially enriching the pharmaceutical stocks.

The steps to purchase a Fortune 500 stock and why they can be a valuable part of your portfolio.

With the Fed expected to keep rates higher throughout this year, the odds of the economy tipping into a recession are rising. Amid ongoing macroeconomic uncertainties, investors may consider buying companies with reliable performance over the years for solid long-term returns. To that end, Pfizer (PFE), Johnson & Johnson (JNJ),…

The highly transmissible 'Kraken' COVID variant is here. Experts say getting boosted is your best protection.

Scientists say there is no evidence to suggest that vaccinations are making COVID "stronger" and that mutations are a normal part of virus evolution.

Johnson & Johnson (JNJ) continued its business momentum in the third quarter of fiscal 2022, driven by steady demand for its products and innovative, advancing portfolio and pipeline. Moreover, the company has a record of raising its dividend for 60 consecutive years. Amid the current uncertain market conditions, this fundamentally…

Johnson & Johnson's consumer health care division, named Kenvue, will have annual sales of around $15 billion.